| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/30/2013 | US8431130 IL-18 binding proteins |
| 04/30/2013 | US8431129 Method of treating fibroproliferative disorders of the heart and lung |
| 04/30/2013 | US8431128 Enterococcus antigens |
| 04/30/2013 | US8431127 Method for treating pruritus comprising administering an NR10 antagonist |
| 04/30/2013 | US8431126 Antibodies that bind polypeptides involved in the process of bone remodeling |
| 04/30/2013 | US8431125 Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteins |
| 04/30/2013 | US8431118 Anti-herpes simplex virus antibodies and methods of use thereof |
| 04/30/2013 | US8431116 Norovirus vaccine formulations |
| 04/30/2013 | CA2531023C Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 04/30/2013 | CA2458995C Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 04/30/2013 | CA2453522C Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 04/30/2013 | CA2435664C Ncc2705-the genome of a bifidobacterium |
| 04/30/2013 | CA2412612C Eg-vegf nucleic acids and polypeptides and methods of use |
| 04/30/2013 | CA2403964C Compositions and methods for dendritic cell-based immunotherapy |
| 04/30/2013 | CA2399321C Adenovirus formulations |
| 04/30/2013 | CA2383154C Baff receptor (bcma), an immunoregulatory agent |
| 04/30/2013 | CA2224256C Method for treating established spontaneous auto-immune diseases in mammals |
| 04/27/2013 | CA2794397A1 Modulation of ul24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection |
| 04/25/2013 | WO2013059786A1 Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease |
| 04/25/2013 | WO2013059784A1 Antigen presenting cancer vaccine |
| 04/25/2013 | WO2013059548A1 Compositions and methods for treating cancer using jak2 inhibitor |
| 04/25/2013 | WO2013059531A1 Anti-gcgr antibodies and uses thereof |
| 04/25/2013 | WO2013059530A2 Peptidomimetic macrocycles |
| 04/25/2013 | WO2013059524A2 Antibodies directed against influenza |
| 04/25/2013 | WO2013059498A1 Mva vectors expressing polypeptides and having high level production in certain cell lines |
| 04/25/2013 | WO2013059493A1 Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
| 04/25/2013 | WO2013059491A1 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| 04/25/2013 | WO2013059439A2 Combination therapy comprising an mmp-14 binding protein |
| 04/25/2013 | WO2013059426A1 Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
| 04/25/2013 | WO2013059412A1 Etanercept formulations stabilized with combinations of sugars and polyols |
| 04/25/2013 | WO2013059411A1 Method for treating cancer with toxoplasma gondii vaccine |
| 04/25/2013 | WO2013059410A1 Etanercept formulations stabilized with xylitol |
| 04/25/2013 | WO2013059408A1 Etanercept formulations stabilized with meglumine |
| 04/25/2013 | WO2013059407A1 Etanercept formulations stabilized with sodium chloride |
| 04/25/2013 | WO2013059406A1 Etanercept formulations stabilized with metal ions |
| 04/25/2013 | WO2013059403A1 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of influenza virus infection |
| 04/25/2013 | WO2013059299A1 Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof |
| 04/25/2013 | WO2013058833A1 Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| 04/25/2013 | WO2013058812A1 Targeted delivery to pancreatic islet endothelial cells |
| 04/25/2013 | WO2013057715A1 Adjuvanted influenza b virus vaccines for pediatric priming |
| 04/25/2013 | WO2013057281A2 Modulation of macrophage activation |
| 04/25/2013 | WO2013057236A1 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens |
| 04/25/2013 | WO2013057235A1 Recombinant nonpathogenic mdv vector providing multivalent immunity |
| 04/25/2013 | WO2013057191A1 Multi-cbv vaccine for preventing or treating type 1 diabetes |
| 04/25/2013 | WO2013056984A1 Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates |
| 04/25/2013 | WO2013056851A2 Stable multiple antigen-binding antibody |
| 04/25/2013 | WO2013056716A1 Pd-l1 based immunotherapy |
| 04/25/2013 | WO2013056453A1 Preparation method and application of injection for needleless injection |
| 04/25/2013 | WO2013056352A1 Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| 04/25/2013 | WO2013056304A1 Influenza immunotherapy |
| 04/25/2013 | WO2013033496A3 Laser adjuvants for enhancing immune response |
| 04/25/2013 | WO2013033319A3 A cluster of neutralizing antibodies to hepatitis c virus |
| 04/25/2013 | WO2013032643A3 Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| 04/25/2013 | WO2013030176A3 Live attenuated influenza virus |
| 04/25/2013 | WO2013028334A3 Use of small molecules in methods for purification of biomolecules |
| 04/25/2013 | WO2013025834A3 Compositions and methods related to antibodies to staphylococcal protein a |
| 04/25/2013 | WO2013025545A3 Drug delivery systems and method of reducing foal infection by treating mares with gallium salts |
| 04/25/2013 | WO2013025446A3 Anti-fzd10 monoclonal antibodies and methods for their use |
| 04/25/2013 | WO2013013038A3 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 04/25/2013 | WO2013009981A9 Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid |
| 04/25/2013 | WO2012177624A3 Focused radiation for augmenting immune-based therapies against neoplasms |
| 04/25/2013 | WO2012174280A3 Methods and compositions for modulating myofibroblast activities |
| 04/25/2013 | WO2012173819A3 Anti-cd3 therapies |
| 04/25/2013 | WO2012170929A3 Monoclonal antibody and antigens for diagnosing and treating lung disease and injury |
| 04/25/2013 | WO2012162629A3 Popcorn shape gold nanoparticle for targeted diagnosis, photothermal treatment and in-situ monitoring therapy response for cancer and multiple drug resistance bacteria |
| 04/25/2013 | WO2012021512A8 Erythrocyte-binding therapeutics |
| 04/25/2013 | WO2012010974A8 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 04/25/2013 | WO2011116954A3 Prophylaxis of colorectal and gastrointestinal cancer |
| 04/25/2013 | US20130102762 Anti-psgl-1 antibodies |
| 04/25/2013 | US20130102760 Immunoglobulin Preparations Having Increased Stability |
| 04/25/2013 | US20130102560 Nutritional composition comprising immunoglobulins and oligosaccharides |
| 04/25/2013 | US20130102548 Pharmaceutical delivery system |
| 04/25/2013 | US20130102495 Sperm-Specific Cation Channel, Catsper1 and Uses Therefor |
| 04/25/2013 | US20130101664 Muc1 ligand traps for use in treating cancers |
| 04/25/2013 | US20130101640 Etanercept Formulations Stabilized with Combinations of Sugars and Polyols |
| 04/25/2013 | US20130101629 Homogenous suspension of immunopotentiating compounds and uses thereof |
| 04/25/2013 | US20130101626 Mucin antigen vaccine |
| 04/25/2013 | US20130101623 Attenuated mycobacterial strain as novel vaccine against tuberculosis |
| 04/25/2013 | US20130101622 Imidazoquinoxaline compounds as immunomodulators |
| 04/25/2013 | US20130101621 Pcv2 immunogenic compositions and methods of producing such compositions |
| 04/25/2013 | US20130101620 Recombinant varicella-zoster virus |
| 04/25/2013 | US20130101619 Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens |
| 04/25/2013 | US20130101618 Chimpanzee adenoviral vector-based filovirus vaccines |
| 04/25/2013 | US20130101617 Env trimer immunogens |
| 04/25/2013 | US20130101615 Methods for preventing or treating a disease or condition associated with mycobacterium avium subspecies paratuberculosis |
| 04/25/2013 | US20130101614 Novel live recombinant booster vaccine against tuberculosis |
| 04/25/2013 | US20130101613 Protective proteins of s. agalactiae, combinations thereof and methods of using the same |
| 04/25/2013 | US20130101612 Vaccine for enveloped viruses |
| 04/25/2013 | US20130101604 Human cytomegalovirus neutralising antibodies and use thereof |
| 04/25/2013 | US20130101601 Antibodies directed against nerve growth factor (ngf) |
| 04/25/2013 | US20130101598 Antagonists of il-6 to prevent or treat thrombosis |
| 04/25/2013 | US20130101597 Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186) |
| 04/25/2013 | US20130101596 Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| 04/25/2013 | US20130101595 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
| 04/25/2013 | US20130101592 S100a4 antibodies and therapeutic uses thereof |
| 04/25/2013 | US20130101590 Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| 04/25/2013 | US20130101589 Polypeptides and antibodies |
| 04/25/2013 | US20130101587 Anti-psgl-1 antibodies |
| 04/25/2013 | US20130101586 Stable multiple antigen-binding antibody |
| 04/25/2013 | US20130101584 Etanercept Formulations Stabilized with Xylitol |